App delivered by L2S2 wins across the board

L2S2 is proud to be associated with C2-AI with responsibility for delivering on their technical programmes and sends many congratulations.

C2-AI has received many accolades for their COMPASS app and its contribution to the response to COVID-19.  A selection of awards that they have received include:

• Winner of Best Global Health Innovation for responding to COVID-19 (at the COGX 2020 Global Leadership Summit and Festival of Ai & Emerging Technology)
• WINNER of COGX 2020 Best Global Innovation overall for responding to COVID-19.
• Named in the Top 10 best digital innovations for a national response COVID-19 by Healthcare UK (which is a collaboration of Dept of Health, NHS England and UKTI)
• Named in the Top 50 best Digital Healthcare Innovations overall by DiT.

The Arm / L2S2 partnership overcomes many of these barriers to healthtech development and deployment.  It provides a trusted ecosystem of highly configurable solutions.

L2S2 is a specialist supplier of compliant solutions for the highly regulated healthcare market.  L2S2’s solutions accelerate development and deployment of new medical-device-grade software products.  They ensure compliant data management ‘out of the box’, connect to established healthcare IT systems and reduce product life cycle costs.  L2S2’s Reassure products also provide a channel to market for new entrants.

The partnership extends L2S2’s solutions with the power of Arm’s mbed IoT operating system and Arm’s Pelion IoT platform for device management and secure data transfer.  Combined, the Arm and L2S2 technologies can greatly accelerate delivery of compliant healthcare at scale.

Compass was developed by L2S2 on the MMDC / Reassure platform.  L2S2 has encapsulated C2-AI’s AI with a secure wrapper that protects the IP and delivered as a Class 1 medical device app in a few months.

C2-AI will also be at the forefront of companies helping the NHS to recover normal services.  C2-AI’s surgical triage app, COMPASS, also developed by L2S2 using the MMDE Reassure platform will be used to prioritise the growing (currently10 million strong) waiting list. This app objectively scores the individual’s risk of mortality and complications, by providing bespoke risk assessments for complications and mortality in less than a minute. It provides a suite of risk assessments for different conditions and procedures creating opportunities to optimise care prior to surgery.

Compass was produced rapidly by L2S2 using MMDC.  It encapsulates AI algorithms developed using  more than 100m health records and has been registered as a Class I medical device by L2S2 using MMDC.

L2S2 is proud to be helping C2-AI to keep patients safe.